Cocrystal Pharma (COCP) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 14.4% versus a loss of 76.7%. Over five years, COCP leads with a -90.5% price change compared with -99.7% for JSPR. Cocrystal Pharma is the larger company by market cap ($20.6 million vs $18.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | JSPR |
|---|---|---|
| Share price | $1.07 | $0.56 |
| Market cap | $20.61M | $18.63M |
| 1-day change | 0.00% | -1.70% |
| YTD return | +9.18% | -69.40% |
| 1-year return | -14.40% | -76.67% |
| 5-year return | -90.51% | -99.66% |
| EPS (TTM) | $-0.76 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.03 | $2.69 |
| 52-week low | $0.76 | $0.315 |
| Distance from 52-week high | -47.29% | -79.18% |
| Analyst consensus | none | none |
| Avg. price target upside | +741.12% | +3471.43% |
| Average volume | 56.00K | 1.37M |
| Shares outstanding | 19.26M | 33.27M |
| Employees | 10 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed JSPR by 62.3 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Healthcare · Biotechnology · 10 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Healthcare · Biotechnology
COCP vs JSPR FAQ
Which is bigger, Cocrystal Pharma or Jasper Therapeutics?
Cocrystal Pharma (COCP) is larger, with a market capitalization of $20.61M compared with $18.63M for Jasper Therapeutics (JSPR).
Which stock has performed better over the past year, COCP or JSPR?
COCP returned -14.40% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.